APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchHepatitis Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hepatitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hepatitis Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatitis Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatitis Vaccine market include Bio Kangtai, ChangSheng, Dynavax, Hissen, IMBCA, KM Biologics, LG Life Sciences, NCPC and Serum Institute, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatitis Vaccine Segment by Company

Bio Kangtai

ChangSheng

Dynavax

Hissen

IMBCA

KM Biologics

LG Life Sciences

NCPC

Serum Institute

Sinovac

Zhejiang Pukang

GSK

Merck

Sanofi

Hepatitis Vaccine Segment by Type

Hepatitis A Vaccines

Hepatitis B Vaccines

Hepatitis Vaccine Segment by Application

Children

Adult

Hepatitis Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hepatitis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatitis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatitis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis Vaccine industry.

Chapter 3: Detailed analysis of Hepatitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatitis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis Vaccine Industry Trends Table 2. Hepatitis Vaccine Industry Drivers Table 3. Hepatitis Vaccine Industry Opportunities and Challenges Table 4. Hepatitis Vaccine Industry Restraints Table 5. Global Hepatitis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Hepatitis Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Hepatitis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Hepatitis Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hepatitis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatitis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Hepatitis Vaccine Company, Product Type & Application Table 13. Global Hepatitis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatitis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hepatitis A Vaccines Table 18. Significant Companies of Hepatitis B Vaccines Table 19. Global Hepatitis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Hepatitis Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Hepatitis Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Hepatitis Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Hepatitis Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Hepatitis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatitis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatitis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatitis Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Hepatitis Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Children Table 30. Significant Companies of Adult Table 31. Global Hepatitis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Hepatitis Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Hepatitis Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Hepatitis Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Hepatitis Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Hepatitis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hepatitis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Hepatitis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Hepatitis Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Hepatitis Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Hepatitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Hepatitis Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Hepatitis Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Hepatitis Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Hepatitis Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Hepatitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Hepatitis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Hepatitis Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Hepatitis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Hepatitis Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Hepatitis Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Hepatitis Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Hepatitis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Hepatitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Hepatitis Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Hepatitis Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Hepatitis Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Hepatitis Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Hepatitis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Hepatitis Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Hepatitis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Hepatitis Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Bio Kangtai Company Information Table 64. Bio Kangtai Business Overview Table 65. Bio Kangtai Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Bio Kangtai Hepatitis Vaccine Product Portfolio Table 67. Bio Kangtai Recent Development Table 68. ChangSheng Company Information Table 69. ChangSheng Business Overview Table 70. ChangSheng Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. ChangSheng Hepatitis Vaccine Product Portfolio Table 72. ChangSheng Recent Development Table 73. Dynavax Company Information Table 74. Dynavax Business Overview Table 75. Dynavax Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Dynavax Hepatitis Vaccine Product Portfolio Table 77. Dynavax Recent Development Table 78. Hissen Company Information Table 79. Hissen Business Overview Table 80. Hissen Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hissen Hepatitis Vaccine Product Portfolio Table 82. Hissen Recent Development Table 83. IMBCA Company Information Table 84. IMBCA Business Overview Table 85. IMBCA Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. IMBCA Hepatitis Vaccine Product Portfolio Table 87. IMBCA Recent Development Table 88. KM Biologics Company Information Table 89. KM Biologics Business Overview Table 90. KM Biologics Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. KM Biologics Hepatitis Vaccine Product Portfolio Table 92. KM Biologics Recent Development Table 93. LG Life Sciences Company Information Table 94. LG Life Sciences Business Overview Table 95. LG Life Sciences Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. LG Life Sciences Hepatitis Vaccine Product Portfolio Table 97. LG Life Sciences Recent Development Table 98. NCPC Company Information Table 99. NCPC Business Overview Table 100. NCPC Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. NCPC Hepatitis Vaccine Product Portfolio Table 102. NCPC Recent Development Table 103. Serum Institute Company Information Table 104. Serum Institute Business Overview Table 105. Serum Institute Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Serum Institute Hepatitis Vaccine Product Portfolio Table 107. Serum Institute Recent Development Table 108. Sinovac Company Information Table 109. Sinovac Business Overview Table 110. Sinovac Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sinovac Hepatitis Vaccine Product Portfolio Table 112. Sinovac Recent Development Table 113. Zhejiang Pukang Company Information Table 114. Zhejiang Pukang Business Overview Table 115. Zhejiang Pukang Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Zhejiang Pukang Hepatitis Vaccine Product Portfolio Table 117. Zhejiang Pukang Recent Development Table 118. GSK Company Information Table 119. GSK Business Overview Table 120. GSK Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. GSK Hepatitis Vaccine Product Portfolio Table 122. GSK Recent Development Table 123. Merck Company Information Table 124. Merck Business Overview Table 125. Merck Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Merck Hepatitis Vaccine Product Portfolio Table 127. Merck Recent Development Table 128. Sanofi Company Information Table 129. Sanofi Business Overview Table 130. Sanofi Hepatitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Sanofi Hepatitis Vaccine Product Portfolio Table 132. Sanofi Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Hepatitis Vaccine Distributors List Table 136. Hepatitis Vaccine Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Hepatitis Vaccine Product Image Figure 2. Global Hepatitis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatitis Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Hepatitis Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hepatitis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hepatitis A Vaccines Image Figure 10. Hepatitis B Vaccines Image Figure 11. Global Hepatitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Hepatitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatitis Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatitis Vaccine Sales Value Share by Type (2021-2032) Figure 17. Children Image Figure 18. Adult Image Figure 19. Global Hepatitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Hepatitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Hepatitis Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Hepatitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hepatitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Hepatitis Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Hepatitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Hepatitis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Hepatitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Hepatitis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Hepatitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Hepatitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Hepatitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Hepatitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Hepatitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Hepatitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Hepatitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Hepatitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Hepatitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Hepatitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Hepatitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Hepatitis Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Hepatitis Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis A Vaccines
  • Hepatitis B Vaccines
Applications
  • Children
  • Adult
Companies covered
  • Bio Kangtai
  • ChangSheng
  • Dynavax
  • Hissen
  • IMBCA
  • KM Biologics
  • LG Life Sciences
  • NCPC
  • Serum Institute
  • Sinovac
  • Zhejiang Pukang
  • GSK
  • Merck
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Hepatitis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatitis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatitis Vaccine Market Dynamics
  1. 2.1 Hepatitis Vaccine Industry Trends
  2. 2.2 Hepatitis Vaccine Industry Drivers
  3. 2.3 Hepatitis Vaccine Industry Opportunities and Challenges
  4. 2.4 Hepatitis Vaccine Industry Restraints
3 Hepatitis Vaccine Market by Company
  1. 3.1 Global Hepatitis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatitis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Hepatitis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Hepatitis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatitis Vaccine Company Product Type and Application
  8. 3.8 Global Hepatitis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatitis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatitis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatitis Vaccine Market by Type
  1. 4.1 Hepatitis Vaccine Type Introduction
  2. 4.1.1 Hepatitis A Vaccines
  3. 4.1.2 Hepatitis B Vaccines
  4. 4.2 Global Hepatitis Vaccine Sales Volume by Type
  5. 4.2.1 Global Hepatitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatitis Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatitis Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatitis Vaccine Sales Value by Type
  9. 4.3.1 Global Hepatitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatitis Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatitis Vaccine Sales Value Share by Type (2021-2032)
5 Hepatitis Vaccine Market by Application
  1. 5.1 Hepatitis Vaccine Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Hepatitis Vaccine Sales Volume by Application
  5. 5.2.1 Global Hepatitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hepatitis Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Hepatitis Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Hepatitis Vaccine Sales Value by Application
  9. 5.3.1 Global Hepatitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Hepatitis Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Hepatitis Vaccine Sales Value Share by Application (2021-2032)
6 Hepatitis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Hepatitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatitis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatitis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Hepatitis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatitis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatitis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatitis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatitis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatitis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Hepatitis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatitis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatitis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatitis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatitis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatitis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Hepatitis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatitis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatitis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Hepatitis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Hepatitis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatitis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatitis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatitis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Hepatitis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatitis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatitis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatitis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatitis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatitis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bio Kangtai
  2. 8.1.1 Bio Kangtai Company Information
  3. 8.1.2 Bio Kangtai Business Overview
  4. 8.1.3 Bio Kangtai Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bio Kangtai Hepatitis Vaccine Product Portfolio
  6. 8.1.5 Bio Kangtai Recent Developments
  7. 8.2 ChangSheng
  8. 8.2.1 ChangSheng Company Information
  9. 8.2.2 ChangSheng Business Overview
  10. 8.2.3 ChangSheng Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ChangSheng Hepatitis Vaccine Product Portfolio
  12. 8.2.5 ChangSheng Recent Developments
  13. 8.3 Dynavax
  14. 8.3.1 Dynavax Company Information
  15. 8.3.2 Dynavax Business Overview
  16. 8.3.3 Dynavax Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dynavax Hepatitis Vaccine Product Portfolio
  18. 8.3.5 Dynavax Recent Developments
  19. 8.4 Hissen
  20. 8.4.1 Hissen Company Information
  21. 8.4.2 Hissen Business Overview
  22. 8.4.3 Hissen Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hissen Hepatitis Vaccine Product Portfolio
  24. 8.4.5 Hissen Recent Developments
  25. 8.5 IMBCA
  26. 8.5.1 IMBCA Company Information
  27. 8.5.2 IMBCA Business Overview
  28. 8.5.3 IMBCA Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 IMBCA Hepatitis Vaccine Product Portfolio
  30. 8.5.5 IMBCA Recent Developments
  31. 8.6 KM Biologics
  32. 8.6.1 KM Biologics Company Information
  33. 8.6.2 KM Biologics Business Overview
  34. 8.6.3 KM Biologics Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 KM Biologics Hepatitis Vaccine Product Portfolio
  36. 8.6.5 KM Biologics Recent Developments
  37. 8.7 LG Life Sciences
  38. 8.7.1 LG Life Sciences Company Information
  39. 8.7.2 LG Life Sciences Business Overview
  40. 8.7.3 LG Life Sciences Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 LG Life Sciences Hepatitis Vaccine Product Portfolio
  42. 8.7.5 LG Life Sciences Recent Developments
  43. 8.8 NCPC
  44. 8.8.1 NCPC Company Information
  45. 8.8.2 NCPC Business Overview
  46. 8.8.3 NCPC Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 NCPC Hepatitis Vaccine Product Portfolio
  48. 8.8.5 NCPC Recent Developments
  49. 8.9 Serum Institute
  50. 8.9.1 Serum Institute Company Information
  51. 8.9.2 Serum Institute Business Overview
  52. 8.9.3 Serum Institute Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Serum Institute Hepatitis Vaccine Product Portfolio
  54. 8.9.5 Serum Institute Recent Developments
  55. 8.10 Sinovac
  56. 8.10.1 Sinovac Company Information
  57. 8.10.2 Sinovac Business Overview
  58. 8.10.3 Sinovac Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sinovac Hepatitis Vaccine Product Portfolio
  60. 8.10.5 Sinovac Recent Developments
  61. 8.11 Zhejiang Pukang
  62. 8.11.1 Zhejiang Pukang Company Information
  63. 8.11.2 Zhejiang Pukang Business Overview
  64. 8.11.3 Zhejiang Pukang Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Zhejiang Pukang Hepatitis Vaccine Product Portfolio
  66. 8.11.5 Zhejiang Pukang Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GSK Hepatitis Vaccine Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Merck Hepatitis Vaccine Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Sanofi
  80. 8.14.1 Sanofi Company Information
  81. 8.14.2 Sanofi Business Overview
  82. 8.14.3 Sanofi Hepatitis Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sanofi Hepatitis Vaccine Product Portfolio
  84. 8.14.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatitis Vaccine Value Chain Analysis
  2. 9.1.1 Hepatitis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatitis Vaccine Sales Mode & Process
  6. 9.2 Hepatitis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatitis Vaccine Distributors
  9. 9.2.3 Hepatitis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst